February 24, 2025 07:31 AM ESTUpdated 10:02 AM

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Ayisha Sharma

News Reporter

Sanofi and Teva’s inflammatory bowel disease candidate could make €1 billion ($1.05 billion) a year by 2032, Leerink analysts said on Sunday. The blockbuster projection …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

FDA approves first drug to treat ultra-rare lipid storage disease

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

How AI can address ongoing challenges in the life sciences industry

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition